Business Wire

AXS and Lawson Entertainment Partner to Enhance Fan Ticketing Experiences in Japan

21.10.2025 20:41:00 CEST | Business Wire | Press Release

Share

AXS, the trusted leader in advanced ticketing and live event technology, today announced the establishment of AXS Tickets, a new joint venture with Lawson Entertainment, one of Japan’s leading entertainment and ticketing companies, marking a major expansion of AXS’s business in Japan.

This partnership builds on AXS’s successful presence in Japan, combining AXS’s world-class technology and global expertise with Lawson Entertainment’s (Lawson Tickets’) deep industry relationships and highly recognized consumer brand. Together, they aim to expand access to live entertainment and sports across Japan.

Since its launch in 2018, AXS Japan has powered ticketing for thousands of events and sold tens of millions of tickets for some of the country’s fastest-growing sports leagues, professional teams, and major event organizers. The creation of AXS Tickets strengthens that foundation — enabling AXS and Lawson Entertainment to deliver a new level of innovation and scale for artists, promoters, venues, and fans nationwide.

Lawson Entertainment operates one of Japan’s largest ticketing businesses, supported by an extensive retail and digital presence and long-standing relationships with sports leagues, teams, promoters, festivals, and venues. Through its partnership with AXS, Lawson Entertainment will leverage AXS’s proven expertise in secure, seamless, and personalized ticketing solutions, while continuing to capitalize on its broad market reach.

The joint venture will combine the full scope of both companies’ services. Lawson Entertainment (Lawson Tickets) plays a central role in Japan’s entertainment ecosystem, spanning sports, live entertainment, theater, art exhibitions, cinemas, livestreaming, classical music and opera, fan club management, and travel. AXS brings to the table advanced platform capabilities such as ID-based ticketing, reliable mobile solutions, dynamic pricing, and data-driven insights — all designed to create safer, more flexible, and more personalized experiences for fans and clients alike.

Ticket sales locations (via AXS’s website or joint venture channels) and in-store purchasing details will be announced at a later date.

The establishment of AXS Tickets in Japan represents a natural evolution of AXS’s existing presence in the market, allowing both brands to better meet the increasingly complex and diverse needs of clients and fans.

“Japan’s live entertainment market is evolving rapidly, and we’re thrilled to help shape its future,” said Motoki Ishikawa, Managing Director of AXS Japan. “By bringing together Lawson Entertainment’s deep regional connections and AXS’s global technology and know-how, AXS Tickets is creating a more seamless, connected, and innovative ticketing experience for fans and clients across Japan.”

“At Lawson Entertainment, our mission has always been to connect fans with the artists, teams, and experiences they love,” said Dai Sakai, Executive Officer of Lawson Entertainment. “Partnering with AXS allows us to build on our trusted brand and deep local history by combining it with AXS’s international network and innovative approach. Together, we’re setting a new standard for live entertainment access and experience in Japan.”

About AXS

AXS is a trusted leader in advanced ticketing and live event technology, providing access to some of the world’s most iconic venues, sports teams, festivals, and global tours. With customized ticketing solutions, innovative technology, and dedicated customer service, AXS partners with over 1,600 of the most recognized brands in sports and entertainment — including LA28 Olympic & Paralympic Games, Coachella Valley Music and Arts Festival, Red Rocks Amphitheatre, The O2 Arena, BNP Paribas Open, WM Phoenix Open, and Stagecoach Country Music Festival.

AXS’s primary and secondary marketplaces and its proprietary AXS Mobile ID technology deliver the easiest and most secure way for fans to buy, sell, and manage tickets.

About Lawson Entertainment

As part of the Lawson Group, Lawson Entertainment operates under the corporate philosophy of “Creating Happiness and Harmony in Our Communities.” The company continuously works to strengthen existing businesses, expand its scope, and enhance services that earn customer trust and loyalty.

Lawson Entertainment’s five core business pillars include:

  • Ticketing (Lawson Tickets)
  • Travel Agency (Lawson Travel)
  • Entertainment retail (HMV & BOOKS)
  • Movie Theater (Lawson United Cinema)
  • Entertainment agency (Double Culture Partners / DCP)

Together, these divisions deliver comprehensive entertainment services, develop new offerings through cross-business synergies, and continue to expand the group’s overall reach.

Lawson Tickets handles a wide range of events — including music, sports, theater, leisure attractions, and film — and is one of Japan’s market leaders in entertainment ticket sales. Fans can purchase tickets 24/7 at approximately 15,000 Lawson and Mini Stop stores nationwide.

In response to changing consumer needs, Lawson Entertainment continues to expand its offerings — from digital ticketing and inbound tourism services to online flight and hotel booking, entertainment tour planning, major event promotion, participatory sports initiatives, and fan club management.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251021393983/en/

Contacts

Media Contact
Ashley Dos Santos
adossantos@axs.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye